SELP and myeloid sarcoma: Finally, compared to control subjects, EMPs-CD62 were augmented in CIS and all the MS forms, although this increase was statistically significant only for CIS patients: 646 ± 195 vs. 418 ± 289 (p < 0.05) (Figure 4C).